Why CDI Prevention Becomes Inevitable with "CDiffControl"
CDI is largely iatrogenic, disproportionately affecting patients ≥65 in hospitals and LTCFs, resulting in prolonged hospital stays, readmissions, increased mortality, and CMS penalties.
The Problem CMS Cannot Avoid
CDI is largely iatrogenic
Triggered primarily by antibiotic use, CDI disproportionately affects patients ≥65 in hospitals and Long-Term Care Facilities (LTCFs).
Clinical and financial consequences
CDI results in:
- Prolonged hospital stays
- Increased readmissions
- Higher mortality rates
- CMS penalties (HACs, readmission metrics)
The Preventable Population Is Known Before Infection
Unlike most diseases, CDI risk is fully identifiable in advance
High-risk criteria:
The Economic Asymmetry That Drives Adoption
Treating 1 CDI Infection
Average CMS cost per CDI case, including extended hospital stays, readmissions, and associated care.
CDI Preventive IgY (36 days)
Complete preventive course for high-risk patients during antibiotic exposure and post-exposure risk window.
Break-even analysis
CMS only needs to prevent ~1 CDI per 60 patients treated to fully pay for prevention.
Even a ~2% absolute reduction in CDI incidence creates net savings.
Internal modeling shows ~2:1 system payback — conservative estimate.
Why Uptake Should Approach 100%
This is not physician-preference driven
Adoption is driven by:
- Budget-positive economics
- Predictable outcomes
- Auditable implementation
- Alignment with CMS incentives
Implementation pathway
Once validated, "CDiffControl" CDI prevention becomes:
- Automatically bundled with antibiotics
- Included in hospital order sets
- Applied at admission or first antibiotic dose
- Enforced through reimbursement policy, not persuasion
Hospitals are paid to avoid CDI. This tool enables them to do it reliably.
Why This Is Different From Existing Approaches
| Existing Approach | Limitation |
|---|---|
| Antibiotic stewardship | Reduces use, doesn't eliminate risk |
| Probiotics | Inconsistent efficacy, safety concerns |
| Environmental cleaning | Post-exposure intervention |
| Diagnostics | Reactive, implemented after infection |
| "CDiffControl" IgY prevention | Acts during antibiotic exposure, pathogen-specific, non-systemic and safe, directly targets CDI pathogenesis |
"CDiffControl" CDI prevention becomes inevitable the moment CMS realizes it saves $30,000 by paying $500.
Methodology Note: Cost estimates based on CMS claims data analysis, peer-reviewed literature on CDI treatment costs, and internal modeling of preventive intervention impact. Population estimates derived from CDC surveillance data and Medicare claims analysis. Economic projections assume conservative efficacy estimates and current reimbursement structures.
